

Updated June 2014

MarketVIEW: Chikungunya virus vaccines (CAT: VAMV005)

Product Name:	Chikungunya virus vaccines
Description	Global vaccine commercial opportunity assessment
Contents	Executive presentation + forecast model
Therapeutic area	Novel vaccines
Publication date	June 2014
Catalogue No	VAMV005

Background

Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia. In some cases the virus can cause recurrent disease, neurological complications and severe neonatal disease (encephalopathy). Although CHIK is endemic in Africa/Southeast Asia, recently outbreaks have occurred in previously CHIK free countries, including China, Papua New Guinea, Laos, New Caledonia and Bhutan. The first documented outbreak of CHIK in the Americas occurred in December 2012: as of April 2014, more than 40,000 probable and confirmed cases were reported. Because there is no specific treatment for CHIK infection many institutions have considered the prospect for a prophylactic vaccine.

This expert report comprises of two deliverables 1) A commercial summary presentation and 2) An Excel-based commercial forecast model which details potential demand (doses) and gross sales revenues (\$USD) in all potential target markets for a prophylactic Chikungunya vaccine. For each target market characteristics and model assumptions are clearly presented along with relevant cases studies of other vaccines currently licensed for travelling populations and private markets of SE Asia. The report has been structured to provide expert guidance as to the commercial viability of a CHIK vaccine.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Chikungunya virus. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research on endemic/travel vaccines **VacZine Analytics** has also been utilised.

PRODUCT CONTENTS:

Updated June 2014 (CAT No: VAMV005)

This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

- Authors Note
- Executive summary
- CHIK vaccines: global value per segment (\$m) to 2035
- CHIK vaccines: global volume per segment (doses) to 2035
- Travel market: by region of departure (value/volume) to 2035
- Endemic markets: by country/region (value/volume) to 2035
- Forecast comparisons: June 2009 vs. June 2014
- Chikungunya virus: commercial model assumptions
- Potential markets for a CHIK vaccine
- Potential markets for a CHIK vaccine: endemic (private)
- Potential markets for a CHIK vaccine: travellers
- Potential markets for a CHIK vaccine: military
- Potential markets for a CHIK vaccine: Western stockpile
- Chikungunya virus: background
- Clinical features
- CHIK: characteristics of an outbreak (2005-06)
- Treatment and prevention
- Reporting and surveillance
- Epidemiology
- CHIK: comparison to other vector borne diseases
- Epidemiology: countries reporting CHIK
- Epidemiology: the Americas
- Chikungunya virus: future dynamics
- Future market trends: drivers & resistors
- Future market trends: outbreak risks
- Future market trends: vector distribution (EU)
- Future market trends: LATAM
- Future market trends: global outbreak risk areas
- Future market trends: vaccines
- Future market trends: cyclical factors
- Future market trends: focus on India
- Chikungunya virus: vaccine R&D pipeline
- R&D pipeline: summary table
- References/Bibliography
- About **VacZine Analytics**

Continued.....

Disclaimer

PAGES: >50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet

Charts – volume/value

Value summary (All)

Volume summary (All)

Traveller markets

US – travellers

EU – travellers

Japan – travellers

Endemic markets (private)

Endemic – private (Africa)

Endemic – private (Other Asia)

Endemic – private (India)

Endemic – private (China)

Endemic – private (LATAM)

Source material

CHIK countries (CDC)

Traveller database (All)

Traveller database (US)

Traveller database (Japan)

Traveller database (EU)

Urban populations – (Africa)

Urban populations – (SE Asia)

Urban populations – (India)

CHIK countries

Back page

Worksheets = 25

Bibliography

1. Chopra A et al. Acute Chikungunya and persistent musculoskeletal pain following the 2006 Indian epidemic. *Epidemiol Infect.* 2012 May;140(5):842-50.
2. Kularatne SA et al. Epidemiology, clinical manifestations, and long-term outcomes of a major outbreak of chikungunya in a hamlet in Sri Lanka, in 2007. *J Trop Med.* 2012;2012:639178.
3. Kosasih H et al. Evidence for endemic chikungunya virus infections in Bandung, Indonesia. *PLoS Negl Trop Dis.* 2013 Oct 24;7(10):e2483
4. Josseran L et al. Chikungunya disease outbreak, Réunion Island. *Emerg Infect Dis.* 2006 Dec;12(12):1994-5.
5. Ravi V. Re-emergence of Chikungunya virus in India. *Indian J Med Microbiol* 2006; 24: 83-4.
6. Qiaoli Z et al. Maiden outbreak of chikungunya in Dongguan city, Guangdong province, China: epidemiological characteristics. *PLoS One.* 2012;7(8):e42830.
7. Horwood PF et al. Outbreak of chikungunya virus infection, Vanimo, Papua New Guinea. *Emerg Infect Dis.* 2013;19(9):1535-8.
8. Souleau C et al. Emergence of chikungunya in Moonlapamok and Khong Districts. *Western Pac Surveill Response J.* 2013 Mar 18;4(1):46-50.
9. European Centre for Disease Prevention and Control. Monitoring current threats: ECDC Communicable Disease Threats Report, week 20/2014
10. Chikungunya virus. US Centers For Disease Control and Prevention (CDC). Geographic Distribution. Available at: <http://www.cdc.gov/chikungunya/geo/index.html>. Accessed: May 2014
11. Tomasello D et al. Chikungunya and dengue autochthonous cases in Europe, 2007-2012. *Travel Med Infect Dis.* 2013 Sep-Oct;11(5):274-84.
12. Ruiz-Moreno D et al. Modeling dynamic introduction of Chikungunya virus in the United States. *PLoS Negl Trop Dis.* 2012;6(11):e1918.
13. Gibney KB et al. Chikungunya fever in the United States: a fifteen year review of cases. *Clin Infect Dis.* 2011 Mar 1;52(5):e121-6.
14. Mizuno Y et al. [First case of chikungunya fever in Japan with persistent arthralgia] *Kansenshogaku Zasshi.* 2007 Sep;81(5):600-1.
15. Cha GW et al. Travel-Associated Chikungunya Cases in South Korea during 2009-2010. *Osong Public Health Res Perspect.* 2013 Jun;4(3):170-5.
16. European Centre for Disease Prevention and Control. Mosquito maps. Available at: http://www.ecdc.europa.eu/en/healthtopics/vectors/vector-maps/Pages/VBORNET_maps.aspx. Accessed: June 2014.
17. World Health Organisation. Available at: www.who.int. Accessed May 2014
18. Directorate Of National Vector Borne Disease Control Programme. Chikungunya Fever Situation in the Country during 2006. Available at: <http://www.nvbdcp.gov.in/>. Accessed: May 2009
19. Muniaraj M. Fading chikungunya fever from India: beginning of the end of another episode? *Indian J Med Res.* 2014 Mar;139(3):468-70.
20. Hoke CH Jr et al. US Military contributions to the global response to pandemic chikungunya. *Vaccine.* 2012 Oct 19;30(47):6713-20.
21. Edelman R et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD 218. *Am J Trop Med Hyg* 2000; 62 : 681-5.
22. Brandler S et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. *Vaccine.* 2013 Aug 12;31(36):3718-25
23. Chu H et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. *Vaccine.* 2013 Jul 18;31(33):3353-60.
24. Tretyakova I et al. DNA Vaccine Initiates Replication of Live Attenuated Chikungunya Virus In Vitro and Elicits Protective Immune Response in Mice. *J Infect Dis.* 2014 Mar 31.
25. Weaver SC et al. Chikungunya virus and prospects for a vaccine. *Expert Rev Vaccines.* 2012 Sep;11(9):1087-101.